Boston Scientific Q2 net sales $5.06B (+22.8% reported); adj. EPS $0.75 beat guidance; raises FY outlook

BOSTON SCIENTIFIC CORP

2025-Q2 EPS reported $0.98 revenue$9,724,000,000

GAAP EPS $0.53 ($797M net income) vs $0.22 a year ago; adjusted EPS $0.75 vs guidance $0.71-0.73.
Q2 organic net sales growth 17.4% (guidance 13-15%); US sales up 30.7% reported.
Cardiovascular segment grew 26.8% reported; MedSurg up 15.7% reported.
FY2025 guidance raised: organic growth 14-15%; adjusted EPS $2.95-2.99 (prior $2.82-2.87).
Closed acquisitions of Intera Oncology and SoniVie; received expanded FDA label for FARAPULSE PFA System.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.